ABT - Abbott Laboratories
| Previous Close | 71.44 |
| Open | 71.74 |
| Bid | 0.00 x 3000 |
| Ask | 0.00 x 2200 |
| Day's Range | 71.41 - 72.23 |
| 52 Week Range | 51.55 - 72.23 |
| Volume | 8,257,303 |
| Avg. Volume | 4,856,987 |
| Market Cap | 126.662B |
| Beta | 1.74 |
| PE Ratio (TTM) | 138.31 |
| EPS (TTM) | 0.52 |
| Earnings Date | Oct 17, 2018 |
| Forward Dividend & Yield | 1.12 (1.62%) |
| Ex-Dividend Date | 2018-10-12 |
| 1y Target Est | 71.81 |
- PR Newswire•10 hours ago
One-Year Results from Real-World Study Showed Abbott's Portico™ Transcatheter Aortic Valve Safely and Successfully Reduced Severe Aortic Stenosis
- Late-breaking data from real-world experience with the first fully repositionable and retrievable valve were consistent with previous results, and support that Portico can be successfully used in various ...
- GuruFocus.com•13 hours ago
5 Companies Hit 52-Week Highs
Recently, multiple companies have all managed to achieve yearly highs
Market Realist•yesterdayWhy JNJ Stock Rose ~2.4% Last Week
On September 21, Johnson & Johnson (JNJ) stock closed at $142.88, ~0.63% higher than the previous day’s closing price of $141.98. JNJ stock returned ~2.4% last week and is currently trading above its 50-day and 200-day moving averages of $135.35 and $128.52, respectively.
- Investor's Business Daily•2 days ago
Stocks Slump As Trade War Intensifies; 3 Med Stocks Rally, Tilray Tumbles
A new round of trade war news pressured Monday's open, while mergers news, rising oil prices and clinical trial results drove some early leaders.
- Investing.com•yesterday
Drug Stocks Rally Midday; Chinese Stocks Take a Hit
Investing.com - Pharmaceutical and biotech stocks led the top gainers in midday trading, while trade war worries dented Chinese stocks trading on Wall Street.
Market Realist•yesterdayWhy ABT Stock Is Trading at a Record High Today
The stock is up ~3.2% during afternoon trading. The jump in ABT’s stock price was triggered by positive study results announced by Abbott Laboratories yesterday for its Mitraclip, a minimally invasive technology for the treatment of mitral valve regurgitation. Mitraclip is one of the key products in Abbott’s portfolio.
- Market Realist•yesterday
A Look at Johnson & Johnson’s Valuation This Month
On September 23, Johnson & Johnson (JNJ) had a market capitalization of $376.8 billion, and its stock closed ~0.63% higher than the day prior. J&J was trading at a forward PE ratio of 16.8x, while its last-12-month PE ratio was 26.1x. Generally, a high forward PE is a sign of an overvalued or high-growth stock.
Market Realist•yesterdayWhat Potential Do Analysts See for JNJ Stock?
Healthcare giant Johnson & Johnson (JNJ), which has a market capitalization of $383.3 billion, submitted two new FDA drug applications this month. However, J&J continues to face litigation battles. The company has recently been asked by the Indian government to provide compensation to patients who received its faulty hip implants. In this article, we’ll look at analysts’ recommendations for JNJ stock for the next 12 months.
- Investing.com•yesterday
Abbott Labs Rises 3.35%
Investing.com - Abbott Labs (NYSE:ABT) rose by 3.35% to trade at $71.36 by 09:33 (13:33 GMT) on Monday on the NYSE exchange.
- Zacks•2 days ago
Why Abbott (ABT) is Poised to Beat Earnings Estimates Again
Abbott (ABT) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
- PR Newswire•2 days ago
Landmark Study Shows Treatment with Abbott's MitraClip® is Superior to Medical Therapy for Advanced Heart Failure Patients with Significant Secondary Mitral Regurgitation
SAN DIEGO, Sept. 23, 2018 /PRNewswire/ -- Abbott (ABT) today announced positive clinical study results from a randomized controlled trial comparing treatment with the MitraClip® device to guideline-directed medical therapy in select patients with secondary (or functional) mitral regurgitation, or a leaky heart valve, as a result of advanced heart failure. The landmark COAPT study met both the primary safety and efficacy endpoints and all secondary endpoints, and showed treatment with MitraClip plus medical therapy was superior to medical therapy alone in reducing rates of heart failure hospitalizations and improving survival at two years.
- Market Realist•5 days ago
Is Abbott Laboratories Trading at a High Valuation in September?
On September 19, Abbott Laboratories (ABT) was trading at a forward PE multiple of 21.8x, while its trailing-12-month PE multiple was 52.4x. Its forward PE and trailing-12-month PE multiples were 19.2x and 55.7x, respectively, a few months ago in May.
- Market Realist•5 days ago
Abbott Laboratories’ 379th Consecutive Quarterly Dividend
On September 13, Abbott Laboratories (ABT) announced its 379th consecutive quarterly dividend, which is payable on November 15. The dividend of $0.28 per share will be paid to shareholders of record as of the close of business on October 15. The company’s annual dividend in 2017 was $1.06, while its indicated annual dividend for 2018 is $1.12 per share. Last year, it paid a quarterly dividend of $0.265 to its shareholders, so its new quarterly dividend represents an increase of ~5.7%.
- Zacks•5 days ago
Abbott Banks on New Approvals and Buyouts, Competition Rife
Abbott's (ABT) receipt of FDA approval for XIENCE Sierra coronary stent system as well as a reimbursement approval in Japan for the same device will help it revive the dull Vascular business.
Market Realist•5 days agoABT Returns Almost Double the S&P 500’s Year-to-Date Gain
As of September 19, Abbott Laboratories (ABT) has registered a rise of ~17% YTD (year-to-date). In the same period, the S&P 500 has risen ~8%. Abbott Laboratories has clearly surpassed the market’s returns so far in 2018.
- Market Realist•5 days ago
Abbott Laboratories Stock Trades at Its 52-Week High in September
On September 18, Abbott Laboratories (ABT) ended the trading day at $68.41, up ~1.1% from its previous trading day’s closing price. The stock has maintained growth momentum over the last year.
Market Realist•5 days agoAnalysts Are Overwhelmingly Bullish on Abbott Laboratories
Abbott Laboratories (ABT) is one of the leading medical technology companies in the world. It offers products across its Medical Devices, Nutrition, Diagnostics, and Established Pharmaceuticals segments, with most of its products having the highest market shares in their respective markets. On July 18, the company released its most recent quarterly results and exceeded analysts’ estimates.
Markit•6 days agoSee what the IHS Markit Score report has to say about Abbott Laboratories.
Abbott Laboratories NYSE:ABT
- Financial Times•6 days ago
[$$] Beto O’Rourke electrifies voters as he takes on Ted Cruz in Texas
Two months before the US midterm elections, Mr Deas, an African-American independent voter who voted for Republican George HW Bush and Democrat Barack Obama, is breaking with his customary political aloofness by carrying a placard for Robert O’Rourke, a charismatic Democratic congressman from El Paso known as “Beto”. “He’s like a white Obama,” said Mr Deas.
- PR Newswire•7 days ago
Abbott Hosts Conference Call for Third-Quarter Earnings
ABBOTT PARK, Ill., Sept. 19, 2018 /PRNewswire/ -- Abbott (NYSE: ABT) will announce its third-quarter 2018 financial results on Wednesday, Oct. 17, 2018 , before the market opens. The announcement will ...
- Zacks•7 days ago
Medical - Products Stock Outlook: Short-Term Pain Inevitable
Medical - Products Stock Outlook: Short-Term Pain Inevitable
- Market Realist•7 days ago
A Look at Hologic Stock’s Recent Performance
On September 17, Hologic (HOLX) ended the day at $39.53. The stock was down ~0.3% from its previous trading day’s closing price of $39.64. The stock has recuperated some of the losses it saw during the first half of fiscal 2018. It witnessed a declining trend after reporting its 52-week high of $45.09 on January 9, 2018.
- Zacks•8 days ago
ABT or PETQ: Which Is the Better Value Stock Right Now?
ABT vs. PETQ: Which Stock Is the Better Value Option?
- Zacks•8 days ago
Here's Why You Should Add Abbott (ABT) to Your Portfolio Now
Abbott (ABT) continues to deliver strong and consistent performance in all segments. The company has also been hogging the limelight within Diabetic Care on progress with its FreeStyle Libre.
